Liz Barrett's bet on UroGen proves timely, as biotech's lead drug scores in key study
Fresh off the high of poaching Novartis oncology group head Liz Barrett into taking charge of the small biotech, UroGen Pharma $URGN on Tuesday reported its lead drug had passed muster in a pivotal study in patients with urothelial cancer.
Patients with low-grade upper tract urothelial cancer (LG UTUC) were enrolled into the phase III OLYMPUS trial. They were given injections of UroGen’s UGN-101 — a formulation of the chemotherapy mitomycin designed to prolong exposure to the urinary tract in order to subvert surgery — once every week for 6 weeks. If tumors disappeared after treatment, patients were eligible to receive additional maintenance therapy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.